Changes in Hong Kong stocks | Baiosaitu-B (02315) raised more than 18%. Net profit returned to mother increased 1.7 times year-on-year in the first three quarters and is expected to fully benefit from AIDD wet test demand transmission

The Zhitong Finance App learned that Biosetu-B (02315) rose by more than 18%. As of press release, it had risen 18.33% to HK$42.58, with a turnover of HK$90.1765 million.

According to news, recently, Baiosetu released its report for the third quarter of 2026. The company achieved operating income of 1,403 billion yuan in the first three quarters, an increase of 49.09%; net profit attributable to shareholders of listed companies was 312 million yuan, an increase of 173.77% year on year; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235 million yuan, an increase of 307.62% year on year. According to the announcement, the increase in the company's performance was mainly due to a sharp increase in the company's pharmacological efficacy services and model animal revenue from the beginning of the year to the end of the reporting period.

According to the League of Nations Minsheng Securities, RenSuper, the next-generation AI-driven antibody discovery platform of Baiosetu, has built a “sequence library+AI+ automation” architecture. Based on more than 1 million full-human antibody sequence training, AI completes structural prediction, epitope inference and functional sequencing, and high-throughput verification of the automated system forms a closed-loop iteration, which is expected to transform difficult drug targets into ADC and multi-specific drug candidates that can be delivered on a large scale. The bank believes that as the demand for AIDD wet experiments is gradually transmitted to the in vivo verification stage, Baiosetu is expected to fully benefit.